Why in News

Serum Institute of India's (SII) indigenously developed quadrivalent HPV vaccine, CERVAVAC, received WHO prequalification effective 25 September 2026. This makes it eligible for procurement by UN agencies (UNICEF, PAHO, Gavi, etc.) and potentially for national HPV immunisation programmes globally.

Key Facts

  • Developer/Manufacturer: Serum Institute of India (SII), Pune.
  • Support: Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC), with contributions from the Gates Foundation and WHO's International Agency for Research on Cancer (IARC).
  • Nature of vaccine: India's first indigenously developed gender-neutral quadrivalent HPV vaccine.
  • Licensed age group: Girls and boys aged 9–26 years.
  • Two-dose schedule for ages 9–14.
  • Three-dose schedule for ages 15–26.
  • HPV types covered (quadrivalent): 6, 11, 16 and 18.
  • Types 16 and 18 — associated with cervical and other cancers.
  • Types 6 and 11 — primarily cause genital warts (low-risk types).

What is WHO Prequalification?

  • WHO prequalification confirms that a vaccine meets required standards of quality, safety and efficacy, based on assessment of product data, manufacturing processes and facilities.
  • It is not a marketing authorisation or a national regulatory approval.
  • However, it provides internationally recognised assurance of vaccine quality and its suitability for procurement by UN agencies and other bulk buyers.

India's HPV Vaccination Programme

  • Launched: 28 February 2026.
  • Beneficiaries: Free HPV vaccination to eligible 14-year-old girls.
  • Vaccine used: Single-dose schedule of Gardasil-4.
  • Coverage: More than 80 lakh doses administered by September 2026 (Union Health Ministry).
  • Important caveat: CERVAVAC's WHO prequalification does not automatically qualify it for inclusion in India's national immunisation programme; inclusion requires separate domestic regulatory and technical (e.g., NTAGI) approval.

Global Linkage: WHO Cervical Cancer Elimination Strategy

The strategy targets the '90-70-90' goals by 2030:

  1. 90% of girls fully vaccinated with HPV vaccine by age 15.
  2. 70% of women screened with a high-performance test by ages 35 and 45.
  3. 90% of women identified with cervical disease receiving treatment (pre-cancer or cancer).

About Serum Institute of India (SII)

  • Founded in 1966 by Cyrus Poonawalla.
  • Headquartered in Pune, Maharashtra.
  • The world's largest vaccine manufacturer by number of doses produced.

Background and Context

  • Human Papillomavirus (HPV) is the most common sexually transmitted infection and is the primary causal agent of cervical cancer, the second most common cancer among Indian women.
  • HPV vaccines are prophylactic (preventive), not therapeutic, and are most effective when administered before exposure to the virus—hence the focus on adolescent girls (and boys).
  • India's earlier HPV vaccine introduction was limited to pilot projects and opportunistic private-sector vaccination, primarily with imported vaccines (Gardasil-4, Cervarix). CERVAVAC marks a shift towards indigenous, affordable supply security.

Significance

  • Public Health: Enhances India's capacity to meet cervical cancer elimination targets and reduces out-of-pocket expenditure on imported vaccines.
  • Atmanirbhar Bharat & Vaccine Diplomacy: Reinforces India's role as the 'pharmacy of the world' and a key supplier to low- and middle-income countries through UN procurement channels.
  • Biotechnology Ecosystem: Validates the DBT–BIRAC–industry partnership model for indigenous vaccine development.
  • Gender-Neutral Approach: Inclusion of boys helps break transmission chains and reduces HPV-related cancers in both sexes (e.g., oropharyngeal, anal cancers).
  • Global Health Governance: WHO prequalification is a key marker of India's regulatory and manufacturing quality standards gaining international acceptance.

Related Provisions and Framework

  • Article 47, Directive Principles of State Policy: Duty of the State to raise the level of nutrition and standard of living and to improve public health.
  • Article 21: Right to health interpreted as part of the right to life.
  • Drugs and Cosmetics Act, 1940 and Rules, 1945: Govern licensing and regulation of vaccines in India (CDSCO approval).
  • National Health Policy, 2017: Emphasises preventive and promotive healthcare and immunisation.
  • Universal Immunisation Programme (UIP) and Mission Indradhanush: Platforms for expanding vaccine coverage.
  • National Technical Advisory Group on Immunisation (NTAGI): Provides technical recommendations for vaccine introduction in the UIP.
  • WHO Cervical Cancer Elimination Initiative (2020): India is a signatory to the global strategy.

Challenges Ahead

  • Ensuring affordability and equitable access, particularly in rural and tribal areas.
  • Addressing vaccine hesitancy and low awareness about HPV and cervical cancer screening.
  • Building cold-chain and delivery infrastructure for adolescent immunisation.
  • Strengthening cervical cancer screening (VIA, Pap smear, HPV DNA testing) alongside vaccination.
  • Integrating CERVAVAC into the national programme subject to NTAGI/CDSCO clearances and price negotiations.